HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group.

Camilleri-Broët, S; Hardy-Bessard, A C; Le Tourneau, A; Paraiso, D; Levrel, O; Leduc, B; Bain, S; Orfeuvre, H; Audouin, J; Pujade-Lauraine, E

Camilleri-Broët, S; Hardy-Bessard, A C; Le Tourneau, A; Paraiso, D; Levrel, O; Leduc, B; Bain, S; Orfeuvre, H; Audouin, J; Pujade-Lauraine, E.

Affiliation

Camilleri-Broët S; Service d'Anatomie Pathologique and Service d'Oncologie, Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, UFR Paris VI, Paris, France. sophie.camilleri-broet@htd.ap-hop-paris.fr

Ann Oncol ; 15(1): 104-12, 2004 Jan.

Article in En | MEDLINE | ID: mdl-14679128

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Neoplasms, Glandular and Epithelial/drug therapy; Neoplasms, Glandular and Epithelial/metabolism; Ovarian Neoplasms/drug therapy; Ovarian Neoplasms/metabolism; Receptor, ErbB-2/metabolism; Adult; Aged; Biomarkers, Tumor/metabolism; Cisplatin/administration & dosage; Clinical Trials, Phase III as Topic; Cyclophosphamide/administration & dosage; Epirubicin/administration & dosage; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasms, Glandular and Epithelial/pathology; Ovarian Neoplasms/pathology; Prognosis; Retrospective Studies; Survival Analysis

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Neoplasms, Glandular and Epithelial / Receptor, ErbB-2 Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2004 Type: Article Affiliation country: France

Search on Google

XML

PubMed Links